Rosen Law Firm is notifying investors in Inovio Pharmaceuticals Inc. (INO) of an ongoing securities class action lawsuit involving shareholders who purchased company securities between October 10, 2023 and December 26, 2025. The litigation alleges that Inovio made materially false statements and omissions regarding its business operations and regulatory prospects.
According to the complaint, Inovio allegedly misrepresented manufacturing deficiencies affecting its CELLECTRA device and overstated the regulatory prospects for INO-3107, its lead therapeutic candidate. The lawsuit further contends that the company failed to disclose that the biologics license application (BLA) submission timeline was unlikely to be achieved as previously communicated to the market.
Investors who sustained losses exceeding $100,000 are encouraged to contact legal counsel promptly, as the lead plaintiff deadline in the class action is set for April 7, 2026. The deadline represents a critical cutoff for investors seeking to participate in the litigation or establish standing as a representative plaintiff.